Here is a list of interesting stocks for the day.
1. Women's apparel retailer Christopher & Banks Corp. (CBK) said Friday that it now expects fourth quarter total net sales to be $96 million to $98 million, compared to its prior guidance of $94 million to $98 million.
Analysts polled by Thomson Reuters currently expect the company to post revenue of $96.92 million for the fourth quarter.
The company continues to expect fourth quarter gross margin to be relatively flat as compared to the comparable prior year period, largely driven by improved merchandise margins offset by deleveraging of occupancy.
LuAnn Via, President and Chief Executive Officer of Christopher & Banks, said, "We are pleased with our performance thus far this quarter in view of the challenging retail environment. Our inventory levels are in line with our expectations and we are comfortable with our position heading into fiscal 2015.
***
2. Off-price branded apparel retailer Burlington Stores, Inc. (BURL) on Friday raised its fourth quarter and fiscal year 2014 outlook based on better-than-expected holiday sales.
For the fourth quarter, the company now expects net sales to grow 9.6% to 10.1%, compared to its prior guidance of a 7.2% to 8.2% growth.
The company raised its fourth quarter adjusted earnings outlook to a range of $1.30 to $1.32 per share from its prior outlook of $1.25 to $1.28 per share.
For the full fiscal year 2014, the company now expects net sales to grow 8.2% to 8.4%, compared to its prior guidance of a 7.5% to 7.8%grwoth.
The company raised its fiscal 2014 adjusted earnings outlook to a range of $1.70 to $1.72 per share from its prior outlook of $1.65 to $1.67 per share.
***
3. Schmitt Industries, Inc. (SMIT) reported second quarter net loss of $69,840, or $(0.02) per share compared with net loss of $163,201, or $(0.05) per share, for the same quarter a year ago.
Q2 total sales increased 0.3%, to $3.15 million from $3.14 million in the year ago quarter.
***
4. Perceptron, Inc. (PRCP) anticipates that revenue for the second quarter will be in excess of $20 million. Analysts expect the company to report revenue of $16.64 million for the quarter.
***
5. Apparel and home décor retailer Gordmans Stores, Inc. (GMAN) said it now expects net sales for the fourth quarter to be between $202 million and $204 million, compared to its previous guidance of $198 million to $202 million.
The company also said it now expects fourth quarter earnings per share to be in the range of $0.05 to $0.08, compared to its previous guidance range of $0.03 to $0.08.
Analysts polled by Thomson Reuters currently expect the company to earn $0.05 per share on revenue of $198.58 million for the fourth quarter.
***
6. TSR, Inc., (TSRI) reported second quarter net income increased to $141,000 or $0.07 per share from $32,000 or $0.02 per share in the prior year quarter
For the second quarter, revenue increased 19.5% to $14.5 million from $12.17 million in the same quarter last year
***
7. Hospital operator Select Medical Holdings Corp. (SEM) said Friday that it expects consolidated net operating revenues for the full year 2015 to be in the range of $3.1 billion to $3.2 billion.
The company also said it expects earnings for the full year 2015 to be in the range of $0.84 to $0.90 per share.
Analysts polled by Thomson Reuters currently expect the company to earn $0.98 per share on revenue of $3.16 billion for the full year 2015.
Select Medical said it will release its fourth quarter and full year 2014 financial results on February 19, 2015 after the market closes.
***
8. Emergent BioSolutions Inc. (EBS) Sunday provided outlook for the full year 2014 and 2015.
For the full year 2014, the company expects earnings of $0.97 to $1.02 per basic share, adjusted earnings of $1.42 to $1.47 per share and revenues of $445 million to $450 million.
The company said the outlook reflects the continued robust BioThrax sales, accounting for approximately $246 million, an expansion of the Biodefense division, initial revenues from the Biosciences product portfolio resulting from the Cangene acquisition, and success in partnering one of the Biosciences preclinical assets.
For the full year 2015, the company expects earnings of $50 million to $60 million, adjusted net income of $60 million to $70 million and revenues of $510 million to $540 million.
For the first quarter of 2015, the company anticipates total revenues of $90 million to $105 million.
***
9. AMAG Pharmaceuticals, Inc. (AMAG) Sunday issued revenue outlook for the full year 2014 and 2015.
AMAG expects fourth-quarter revenues of $52.8 million to $54.5 million. This includes about $6.0 million of revenue recognized from AMAG's collaboration agreement with Takeda Pharmaceutical Co. Ltd. for commercialization of Feraheme outside of the U.S., which was mutually terminated in December 2014.
Fourth-quarter net product sales is expected to be between $47.2 million and $48.2 million, including between $23.8 million and $24.3 million of sales from Feraheme in the U.S. and between $23.1 million and $23.6 million of sales from Makena.
Analysts polled by Thomson Reuters currently estimate revenues of $35.64 million for the quarter. Analysts' estimates typically exclude one-time items.
For the full year 2014, the company expects revenues of $123.8 million to $125.5 million, including $14.0 million revenue from collaboration agreement with Takeda.
Analysts currently estimate revenues of $106.59 million for the 2014.
Net product sales is expected to be between $110.1 million and $111.1 million. U.S. Feraheme net sales are expected to be between $85.8 million and $86.3 million and Makena sales are expected to be between $23.1 million and $23.6 million.
For the full year 2015, the company expects revenue of between $380 million and $420 million, including product sales of $335 million to $375 million.
Analysts currently estimate revenues of $367.50 million for 2015.
***
For comments and feedback contact: editorial@rttnews.com
Business News